Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

BACKGROUND: Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to reimbursement policies requiring patients to try multiple traditional preventive...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ja Bin, Lange, Kristin Sophie, Fitzek, Mira, Overeem, Lucas Hendrik, Triller, Paul, Siebert, Anke, Reuter, Uwe, Raffaelli, Bianca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614330/
https://www.ncbi.nlm.nih.gov/pubmed/37899428
http://dx.doi.org/10.1186/s10194-023-01682-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614330/
https://www.ncbi.nlm.nih.gov/pubmed/37899428
http://dx.doi.org/10.1186/s10194-023-01682-2

Ejemplares similares